Fluoxetine 100 ml

Flunixine 50 mg, first dose daily until injected intravenously once daily and up to 5 days according to the treatment of sepsis or shock associated with gastrointestinal symptoms and other diseases threatening blood supply to the gastrointestinal tract: 25 mg/kg (1 ml per 200 kg) every 6-8 hours. Do not use other non-steroidal anti-inflammatory drugs together at the same time or within 24 hours, as some non-steroidal anti-inflammatory drugs are highly bound to plasma proteins and compete with other highly bound drugs, which may lead to albumin levels in the injection solution. 101 noitasial for cattle and horses 202101 Flunixine (in the form of Flunixine Meglumine) Active ingredients and other contents Each ml contains: Flunixine in the form of Flunixine Meglumine 50 mg, preservative 5 mg, dihydrate sulfoxylate, formaldehyde, sodium 2.5. Clear colorless liquid. Toxic effects. Not used before 48 hours of expected delivery. DIOVB. The recommended dose is 2.2 mg of Flunixine. Usage may involve additional risks with animals under 6 weeks old or older animals if the drug cannot be avoided. Dosing per kg of animal weight is equivalent to 2 ml per kg of body weight, injected intravenously, and repeated if necessary every 24 hours for up to 5 consecutive days. Animals with reduced dose and clinical management to avoid ion or art mont 120. Use of the product with any animals suffering from dehydration or low blood volume is not recommended. 12000 Advice on correct usage. Volume of blood fluids or low pressure only in case of poisoning. Do not use in case of kidney or liver disease, or if there is a possibility of bleeding or stomach ulcer. If there is evidence of disease, avoid using the product with nephrotoxic drugs due to the presence of propylene glycol solvent. Severe shock may occur, which can be life-threatening, but rarely. Therefore, the solution should be injected slowly and at approximately body temperature. Do not puncture the cap more than 50 times. Use a withdrawal syringe to avoid puncturing the cap. During pregnancy and lactation, 10000 cows can use the product in pregnant cows. The withdrawal period should not be exceeded. Animals should not be slaughtered for human consumption during treatment. Slaughter for human consumption can only occur after 7 days from the last treatment date. The product is for bovines. The last treatment date is indicated. Horses: The product is not used in pregnant mares, and safety studies in pregnant mares are not available. Milk should not be taken for human consumption during treatment. Milk can be taken for human consumption from treated cows after 36 hours. User warnings: Avoid contact with eyes and direct contact with skin. If accidental contact occurs with the eyes, rinse thoroughly with water and seek medical advice immediately. Avoid self-injection by mistake. Avoid potential allergic reactions and skin contact. Storage precautions: Do not store above 30°C. Keep the bottle in the outer carton to protect from light. Wear gloves during use. The product may cause reactions in allergic individuals. Do not use in animals without blood fluids suffering from colic with intestinal obstruction. Simulgampumpslavone: Side effects. If any serious effects or other adverse reactions not mentioned in this leaflet are observed, please inform the veterinarian. For gastrointestinal tract issues, ulcers, and possible kidney damage in dehydrated or low-fluid animals, rare allergic reactions have been reported. For veterinary use only. Special disposal precautions for unused products and waste: Flunixine Meglumine is a non-steroidal anti-inflammatory drug. Unwanted effects include irritation. Keep out of reach of children. Do not use after the expiration date printed on the carton and label. After the first dose, use the product within 28 days. Dispose of any unused product after opening the package. Dispose of any unused products or empty containers according to local regulatory waste disposal instructions. The expiry date must be specified during use and on the label, which is the date by which any remaining product must be disposed of. Other information: Special warnings. Pack sizes. Studies on overdose in target species show that the product tolerates overdose. It comes in multi-dose bottles of 50 ml, 100 ml, 250 ml. Gastrointestinal toxicity. If used as an adjunct, monitor closely for compatibility. Avoid intra-arterial injections. Target species: Cattle and horses. Bovine Jun 0. Dose per species, method, and route of use: Flunixine Meglumine injections in cattle and horses by intravenous injection. Do not exceed the recommended dose or treatment duration. Horses: In case of horse colic, the recommended dose is 1.1 mg of Flunixine per kg of animal weight, equivalent to 1 ml per 45 kg of body weight, injected intravenously. The treatment can be repeated once or twice if colic recurs. Flunixine injections have shown some benefit in treating pulmonary edema. Flunixine Meglumine is a potent non-steroidal analgesic with anti-inflammatory, antipyretic, and blood toxicity-reducing effects. It is preferable not to use other NSAIDs that inhibit prostaglandin synthesis in animals under general anesthesia until full recovery. The manufacturing company is Norbrook Laboratories Limited, Ireland, BT356. The use of NSAIDs is prohibited according to racing rules and other competitive event regulations. Horses prepared for racing and competition should be treated only when necessary, following local regulations. The cause of underlying inflammation or colic should be identified and treated. The recommended dose is 1.1 mg of Flunixine per kg of body weight, equivalent to 1 ml per 45 kg, for use in cases of bone and muscle diseases. The animal's body weight.